| Originator: |
|
National Patient Safety Alert - DHSC
|
 |
|
|
- Care Trusts
- Mental Health Trusts
- Specialists Trusts
- Learning Disabilities Trusts
- Mental Health & Social Care Trusts
- Ambulance Trusts
- Mental Health & Learning Disabilities Trusts
- Acute Trusts
- Community Trusts
|
|
|
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Regional Offices
- Social Care Providers (registered with CAS)
- Special Health Authorities
- Territorial CMOs in Northern Ireland, Scotland & Wales
- GP - Locum
- NHS 111 and Out of hours providers
- GP Practices
- Integrated Care Boards
- DHSC Supply Disruption - Medicines
- Community Pharmacy
- Primary Care Networks
- GP Practices 1
|
| Title: |
|
Shortage of Antimicrobial Agents Used in Tuberculosis (TB) Treatment
|
| Broadcast content: |
|
The following antimicrobial medicines used to treat
tuberculosis (TB) will be intermittently available until at least the end of
2025:
- Rifampicin 150mg and 300mg
capsules
- Rifampicin 600mg IV
solution for infusion
- Rifampicin 100mg/5ml oral suspension
- Rifinah® 300
tablets (rifampicin 300mg / isoniazid 150mg)
- Rifater®
tablets (rifampicin 120mg / isoniazid 50mg/ pyrazinamide 300mg)
- Voractiv®
tablets (rifampicin 150mg/ isoniazid 75mg / pyrazinamide 400mg / ethambutol
275mg)
- Pyrazinamide 500mg tablets
Ethambutol tablets, Isoniazid tablets, and Rifinah® 150
tablets (rifampicin 150 mg / isoniazid 100 mg) and Mycobutin® (rifabutin)
150mg capsules remain available but cannot support a full increase in demand. This National Patient Safety Alert provides further background, clinical information and actions for providers.
|
| Additional information: |
|
NHS Regions: please cascade this alert to community pharmacy contractors.
|
| Action underway deadline: |
|
31-Jul-2025
|
| Action complete deadline: |
|
15-Aug-2025
|